When is Benlysta's Key Patent Expected to Expire?
Benlysta's primary patent, U.S. Patent No. 8,575,307, is scheduled to expire on June 28, 2027 [1]. This patent covers certain formulations of the drug.
What About Other Patents Related to Benlysta?
Beyond the '307 patent, there are other patents associated with Benlysta, including those related to its manufacturing process and additional formulations [2]. DrugPatentWatch.com tracks these patents and their expiration dates, which can influence the market entry of generic versions [2].
Could Generics Be Available Before the Main Patent Expires?
The expiration of the primary patent does not always guarantee immediate generic competition. Other patents, such as those covering manufacturing methods or specific uses, could potentially extend market exclusivity or be subject to legal challenges [2]. The U.S. Food and Drug Administration (FDA) also grants periods of exclusivity that can precede or follow patent expiration [3].
Who Makes Benlysta?
Benlysta is manufactured by GlaxoSmithKline [4].
What is Benlysta Used For?
Benlysta is a treatment for systemic lupus erythematosus (SLE) in adult and pediatric patients and is also approved for active lupus nephritis in adult patients [4]. It works by inhibiting B-lymphocyte stimulator (BLyS), a protein involved in the survival and maturation of B cells, which play a role in lupus [5].
How Does Benlysta's Patent Situation Compare to Similar Treatments?
The patent landscape for biologic drugs like Benlysta is complex, with multiple patents often covering different aspects of the drug [2]. This can differ from small molecule drugs where patent protection might be more straightforward. Companies often seek to extend exclusivity through new formulations or delivery methods, leading to a staggered expiration of patent rights [2].
What Are the Potential Impacts of Patent Expiry on Benlysta's Availability and Cost?
Upon patent expiration and the cessation of other exclusivity periods, the potential for generic or biosimilar competition increases. This competition is generally expected to lead to lower prices and increased accessibility for patients [3].
What Litigation is Associated with Benlysta's Patents?
Information regarding specific patent litigation for Benlysta may be available through legal databases and patent watch services [2]. Patent challenges are common in the pharmaceutical industry as companies seek to bring generic or biosimilar versions to market.
What Clinical Data Supports Benlysta's Efficacy?
Benlysta's efficacy has been demonstrated in clinical trials for both lupus and lupus nephritis. Studies have shown its ability to reduce disease activity and prevent flares [4].
Sources
1. https://drugpatentwatch.com/brands/benlysta/patents
2. https://drugpatentwatch.com/
3. U.S. Food & Drug Administration. (n.d.). Exclusivity & Patent Data.
4. GlaxoSmithKline. (n.d.). Benlysta Prescribing Information.
5. https://www.gene.com/download/f91593a50d5579c3d7c349f1c04115a200c994c0/tecentriq_pi.pdf